BioSpace News Archive

7D Surgical announced today that it has received approval from the Health Sciences Authority (HSA) in Singapore for its innovative Machine-vision Image Guidance System (MvIGS) for spinal navigation. In addition, 7D Surgical has already completed its first system sale through its distribution partnership with Transmedic, a premier medical t

Looking to grow by scaling operations and accelerating R&D efforts, Kebotix, a Cambridge-based technology platform company for new chemicals and materials, is extending its labs operations in the Boston area at C2I, a chemistry-focused accelerator in Woburn.

OpenEye Scientific (OpenEye) and CHDI Foundation (CHDI) today announced a research collaboration to identify novel small-molecule therapeutics for Huntington’s disease (HD) utilizing Orion, OpenEye’s cloud-native molecular design platform.

Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional content of crops, today announced that it will release its financial and business results for the second quarter and first half of 2020 after market close on August 13, 2020 .

Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the “Ordinary Shares”) on the standard listing segment of the Official List of the Financial Conduct Authority (the “Official List”) and admission to trading on the London Stock Exchange plc’s

Gillette Children’s Specialty Healthcare is the first US hospital to image patients with EOSedge

BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will present at the Proactive Investors One2One Virtual Event on August 4, 2020.

Obalon Therapeutics, Inc., a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announced its financial results for the second quarter ended June 30, 2020.

IMARA Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the U.S. Food and Drug Administration has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, IMR-687, for the treatment of beta-thalassemia.

BOSTON and LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 6, 2020, at 8:00 a.m. ET to review business updates and its second quarter 2020 financial results. A live webcast will be available under “News & Events” in the Investors & Media section of the company’s website at www.orchard-tx.com . The conference call can be acce